TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24255597

Group type: EXPERIMENTAL
Intervention: Micronutrient supplement (Perfectil® Platinum)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 21804509

Group type: EXPERIMENTAL
Intervention: Oral levofloxacin 750mg once daily for 7 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Injectable levofloxacin 500mg once daily for 7 days
Number of subjects: 100
Study: 19366978

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 105

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 105
Study: 16452280

Group type: EXPERIMENTAL
Intervention: Collaborative care (medication and counseling for up to 12 months)
Number of subjects: 1602

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1602

Group type: EXPERIMENTAL
Intervention: Receipt of preferred treatment
Number of subjects: 1602
Study: 15265539

Group type: EXPERIMENTAL
Intervention: Stress ('public speech')
Number of subjects: 12

Group type: COMPARATOR
Intervention: Good oral hygiene
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Plaque accumulation
Number of subjects: 12
Study: 11737924

Group type: EXPERIMENTAL
Intervention: MDT-driven extubation protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 0
Study: 9002119

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin alone (Group I)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus inhaled amikacin (Group II)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ciprofloxacin (both groups)
Number of subjects: 44
Study: 8431048

Group type: EXPERIMENTAL
Intervention: Indomethacin and thymopentin (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Indomethacin (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thymopentin (added to indomethacin in group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (group C)
Number of subjects: 60
Study: 31399540

Group type: EXPERIMENTAL
Intervention: Combined perineural dexmedetomidine (1 µg/kg) and dexamethasone (10 mg) in 2 mL (RSM group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Perineural dexamethasone (10 mg) in 2 mL (RS group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Perineural dexmedetomidine (1 µg/kg) in 2 mL (RM group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ropivacaine with normal saline (R group)
Number of subjects: 80
Study: 30671061

Group type: EXPERIMENTAL
Intervention: Severe injury patients (burn, trauma, septic shock)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Healthy volunteers (HV)
Number of subjects: 313
Study: 26466937

Group type: EXPERIMENTAL
Intervention: Risedronate (48-week treatment)
Number of subjects: 885
Study: 24706729

Group type: EXPERIMENTAL
Intervention: Experimental intervention to promote longer duration and exclusivity of breastfeeding (n = 16 sites)
Number of subjects: 13000

Group type: COMPARATOR
Intervention: Control intervention of continuing usual care (n = 15 sites)
Number of subjects: 13000

Group type: EXPERIMENTAL
Intervention: Experimental intervention
Number of subjects: 13000
Study: 22572234

Group type: EXPERIMENTAL
Intervention: Intermittent bolus injection of 0.375% ropivacaine into intrapleural space (IPA group, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous epidural analgesia with 0.375% ropivacaine (TEA group, n = 20)
Number of subjects: 40
Study: 19908105

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg x kg(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ketamine-priming
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Priming
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 120
Study: 17929018

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Liposomal amphotericin B (L-AmB)
Number of subjects: 100
Study: 17053894

Group type: EXPERIMENTAL
Intervention: Bread meal before itraconazole administration
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Rice meal before itraconazole administration
Number of subjects: 144
Study: 12514652

Group type: EXPERIMENTAL
Intervention: Patients without angina
Number of subjects: 553

Group type: COMPARATOR
Intervention: Patients with recurrent angina
Number of subjects: 553
Study: 10376571

Group type: EXPERIMENTAL
Intervention: Raloxifene, 60 mg, 2 tablets daily
Number of subjects: 7705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study: 8629721

Group type: EXPERIMENTAL
Intervention: New treatment (specific details not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (specific details not provided)
Number of subjects: 0
Study: 1381330

Group type: EXPERIMENTAL
Intervention: Combaren (diclofenac-Na 50 mg + codeine phosphate 50 mg)
Number of subjects: 184

Group type: COMPARATOR
Intervention: diclofenac-Na 50 mg (Voltaren 50)
Number of subjects: 184
Study: 6421009

Group type: EXPERIMENTAL
Intervention: 40 mg ISDN (acute administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg ISDN (chronic treatment, four doses daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg ISDN (acute administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg ISDN (long-term treatment, twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.8 mg NTG (sublingual during treatment with 40 mg ISDN)
Number of subjects: 0
Study: 31011758

Group type: EXPERIMENTAL
Intervention: Ivosidenib 250 mg, 500 mg, or 1000 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ivosidenib 500 mg with high-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ivosidenib 250 mg with itraconazole 200 mg once daily
Number of subjects: 0
Study: 30248052

Group type: COMPARATOR
Intervention: Antipsychotics, citalopram, or placebo (duration: up to 36 weeks, mean 252±52 days)
Number of subjects: 421
Study: 25023458

Group type: EXPERIMENTAL
Intervention: Therapeutic apheresis with Albutein® 5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with therapeutic apheresis and haemopheresis with Albutein® and intravenous immunoglobulin (Flebogamma® DIF)
Number of subjects: 0
Study: 24057428

Group type: EXPERIMENTAL
Intervention: Upper-body endurance training (ET), 10 sessions
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (CON), standard individualized MS rehabilitation, n = 5
Number of subjects: 11
Study: 23405791

Group type: EXPERIMENTAL
Intervention: Compound Xuanju Capsule (CXC) at 3 g tid plus sildenafil at 50 mg an hour before sexual activity
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sildenafil alone at 100 mg an hour before sexual activity
Number of subjects: 36
Study: 19093205

Group type: EXPERIMENTAL
Intervention: 15 mg of Taiproton (generic lansoprazole)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 15 mg of Tapizol (generic lansoprazole)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 15 mg of Lansoral (generic lansoprazole)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Original lansoprazole (Takepron)
Number of subjects: 8
Study: 17893038

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (normocholesterolemic patients)
Number of subjects: 60
Study: 15108115

Group type: EXPERIMENTAL
Intervention: Intraabdominal pressure (IAP) raised from 12 to 20 mmHg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intraabdominal pressure (IAP) at 12 mmHg
Number of subjects: 22
Study: 11672828

Group type: EXPERIMENTAL
Intervention: 0.50 microg/kg rHuIL‐12
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 0.25 microg/kg rHuIL‐12
Number of subjects: 106

Group type: COMPARATOR
Intervention: 0.03 microg/kg rHuIL‐12
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 0.10 microg/kg rHuIL‐12
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 0.5 microg/kg rHuIL‐12
Number of subjects: 106
Study: 9594519

Group type: EXPERIMENTAL
Intervention: Continuous epidural injection of buprenorphine (0.2 mg) with 0.25% bupivacaine (40 ml) for 24 hours (Group A)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Bolus injection of buprenorphine (0.2 mg) followed by continuous injection of buprenorphine (0.2 mg) with 0.25% bupivacaine (40 ml) for 24 hours (Group B)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Bolus injection of buprenorphine (0.2 mg) followed by continuous buprenorphine infusion with normal saline (Group C)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Continuous epidural injection of buprenorphine (Group C)
Number of subjects: 104
Study: 8207739

Group type: EXPERIMENTAL
Intervention: Ro 42-5892 (100 mg once daily orally)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ro 42-5892 (10 mg intravenously)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 2530925

Group type: EXPERIMENTAL
Intervention: 75 micrograms fentanyl with 12 ml of 0.25% plain bupivacaine
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 15 micrograms sufentanil with 12 ml of 0.25% plain bupivacaine
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (saline with 12 ml of 0.25% plain bupivacaine)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 75 micrograms fentanyl
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 15 micrograms sufentanil
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 124
Study: 78150

Group type: EXPERIMENTAL
Intervention: metiamide
Number of subjects: 68

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 68
Study: 30851458

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 80
Study: 28632487

Group type: EXPERIMENTAL
Intervention: Cytarabine plus idarubicin (AI)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Cytarabine plus high-dose daunorubicin (AD)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Cytarabine plus idarubicin (AI) in patients with FLT3 ITD mutation
Number of subjects: 299

Group type: COMPARATOR
Intervention: Cytarabine plus high-dose daunorubicin (AD) in patients with FLT3 ITD mutation
Number of subjects: 299
Study: 25580869

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 393

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 393
Study: 24019048

Group type: EXPERIMENTAL
Intervention: Retention of jejunal mucosa (Group A)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Removal of jejunal mucosa (Group B)
Number of subjects: 46
Study: 21624655

Group type: EXPERIMENTAL
Intervention: dorzolamide/timolol
Number of subjects: 25

Group type: COMPARATOR
Intervention: brinzolamide/timolol
Number of subjects: 25
Study: 19796205

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with house dust mite extracts
Number of subjects: 194
Study: 16500336

Group type: EXPERIMENTAL
Intervention: Vitamin E with conjugated equine estrogen (CEE) (0.625 mg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: CEE (0.625 mg) plus medroxyprogesterone acetate (MPA) (2.5 mg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 75
Study: 15849968

Group type: EXPERIMENTAL
Intervention: VIMANG for 6 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 10955327

Group type: EXPERIMENTAL
Intervention: naproxen 500 mg bid (n = 1,099)
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: celecoxib 50 mg bid (n = 690)
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: celecoxib 100 mg bid (n = 1,131)
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: celecoxib 200 mg bid (n = 1,125)
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: celecoxib 400 mg bid (n = 434)
Number of subjects: 5000

Group type: COMPARATOR
Intervention: placebo (n = 1,136)
Number of subjects: 5000
Study: 8968014

Group type: EXPERIMENTAL
Intervention: Low-dose chlorthalidone (12.5-25.0 mg/d) with step-up to atenolol (25.0-50.0 mg/d) or reserpine (0.05-0.10 mg/d)
Number of subjects: 4736

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736
Study: 1316075

Group type: EXPERIMENTAL
Intervention: Lomefloxacin (400 mg once daily)
Number of subjects: 727

Group type: COMPARATOR
Intervention: Norfloxacin (400 mg twice daily)
Number of subjects: 727
Study: 2991475

Group type: EXPERIMENTAL
Intervention: Intravenous hyperalimentation (IVH)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (no IVH)
Number of subjects: 119
Study: 29901417

Group type: EXPERIMENTAL
Intervention: Exercise + supplement (ES) group
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Exercise + placebo (EP) group
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Supplement (S) group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 32
Study: 28117244

Group type: EXPERIMENTAL
Intervention: Radial access during coronary angiography (CA)
Number of subjects: 21675

Group type: EXPERIMENTAL
Intervention: Radial access during percutaneous coronary intervention (PCI)
Number of subjects: 21675

Group type: COMPARATOR
Intervention: Femoral access during coronary angiography (CA)
Number of subjects: 21675

Group type: COMPARATOR
Intervention: Femoral access during percutaneous coronary intervention (PCI)
Number of subjects: 21675
Study: 26335787

Group type: EXPERIMENTAL
Intervention: Standard antibiotics plus pidotimod (PDT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard antibiotics alone
Number of subjects: 20
Study: 23219519

Group type: EXPERIMENTAL
Intervention: BioXcell (CS)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: BioXcell (FT)
Number of subjects: 524

Group type: COMPARATOR
Intervention: AndroMed (CS)
Number of subjects: 524

Group type: COMPARATOR
Intervention: AndroMed (FT)
Number of subjects: 524

Group type: COMPARATOR
Intervention: AndroMed (young rams)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Overall (intracervical AI)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Overall (intrauterine AI)
Number of subjects: 524
Study: 21538780

Group type: EXPERIMENTAL
Intervention: MPH bandage
Number of subjects: 112

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 112
Study: 18496296

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg daily (n=27)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg daily (n=28)
Number of subjects: 50
Study: 16796157

Group type: EXPERIMENTAL
Intervention: Reduced-osmolarity ORS solution (245 mmol/L)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Standard WHO-ORS solution (311 mmol/L)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 176
Study: 12657118

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b plus radiation therapy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 74
Study: 11048902

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 to 25 mg orally once daily for 18 weeks)
Number of subjects: 48
Study: 9072308

Group type: EXPERIMENTAL
Intervention: 25 mg dolasetron
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: 50 mg dolasetron
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: 100 mg dolasetron
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: 200 mg dolasetron
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: All doses of dolasetron
Number of subjects: 307
Study: 8471122

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study: 3089576

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31724764

Group type: EXPERIMENTAL
Intervention: Double-layer absorbable suture
Number of subjects: 24

Group type: COMPARATOR
Intervention: Single-layer absorbable suture
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Unidirectional barbed suture
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bidirectional barbed suture
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single-layer unidirectional barbed suture
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single-layer bidirectional barbed suture
Number of subjects: 24
Study: 29859385

Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU every 2 weeks) plus omega-3 fatty acid (2000 mg/day)
Number of subjects: 60
Study: 27291883

Group type: EXPERIMENTAL
Intervention: fampridine
Number of subjects: 18
Study: 24420547

Group type: EXPERIMENTAL
Intervention: 100,000 U oral vitamin D3 every 2 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 68
Study: 23319503

Group type: EXPERIMENTAL
Intervention: 1-hour physician-targeted interactive educational session and patient information handout
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: 1-hour physician-targeted interactive educational session
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 256
Study: 21427901

Group type: EXPERIMENTAL
Intervention: Tetrahydrozoline hydrochloride
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oxymetazoline hydrochloride
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epinephrine hydrochloride
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AlCl3
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fe2(SO4)3
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study: 18047578

Group type: EXPERIMENTAL
Intervention: Discharge training and counselling provided by a researcher
Number of subjects: 109

Group type: COMPARATOR
Intervention: Routines provided by a nurse (Control)
Number of subjects: 109
Study: 16928483

Group type: EXPERIMENTAL
Intervention: Pexelizumab
Number of subjects: 3099

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 3099
Study: 14585251

Group type: EXPERIMENTAL
Intervention: Atenolol 50mg o.d. (group A)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Atenolol 50mg o.d. (group B)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Atenolol 50mg o.d. (group C)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sildenafil 50mg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 11130154

Group type: EXPERIMENTAL
Intervention: Own brand of smokeless tobacco
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine-free smokeless tobacco
Number of subjects: 0

Group type: COMPARATOR
Intervention: No smokeless tobacco (abstinence)
Number of subjects: 0
Study: 9181760

Group type: EXPERIMENTAL
Intervention: Cord blood hyperviscosity
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normal cord blood viscosity
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cord blood hyperviscosity (not polycythemic)
Number of subjects: 23
Study: 8266016

Group type: EXPERIMENTAL
Intervention: 200 mg sulglycotide three times daily (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Indistinguishable placebo (n = 50)
Number of subjects: 100
Study: 2885185

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg kg‐1
Number of subjects: 60
Study: 29705454

Group type: EXPERIMENTAL
Intervention: Hippotherapy (12 weeks, 1 time/week, 45 min)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 44
Study: 27086046

Group type: EXPERIMENTAL
Intervention: Mental Incisal Nerve Block (MINB) with 2 mL 2% lidocaine with 1:200,000 epinephrine and a mock IANB with 2 mL sterile saline
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Inferior Alveolar Nerve Block (IANB) with 2 mL 2% lidocaine
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Combination of MINB and IANB with 2 mL each of 2% lidocaine
Number of subjects: 153
Study: 25065535

Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing and cognitive behavioural therapy (MI-CBT) intervention (up to 12 sessions over 4.5 months) with standard care
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Long motivational interviewing and cognitive behavioural therapy (MI-CBT) intervention (up to 24 sessions over 9 months) with standard care
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 110
Study: 22475399

Group type: EXPERIMENTAL
Intervention: Nicardipine PLGA
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nimodipine PLGA
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo PLGA
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Mibefradil PLGA
Number of subjects: 19
Study: 20163375

Group type: EXPERIMENTAL
Intervention: Renzapride 4 mg daily
Number of subjects: 1798

Group type: EXPERIMENTAL
Intervention: Renzapride 2 mg b.d.
Number of subjects: 1798

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1798

Group type: EXPERIMENTAL
Intervention: Renzapride (both dosages)
Number of subjects: 1798

Group type: EXPERIMENTAL
Intervention: Renzapride
Number of subjects: 1798
Study: 17453011

Group type: EXPERIMENTAL
Intervention: Occupational therapy (OT) program combined with neuromotor rehabilitation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Neuromotor rehabilitation only (Control)
Number of subjects: 36
Study: 20821896

Group type: EXPERIMENTAL
Intervention: Cash transfer program for poor mothers
Number of subjects: 0
Study: 19810295

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 30
Study: 12186803

Group type: EXPERIMENTAL
Intervention: Abnormal renal function (creatinine clearance <70 mL/min) in the STE group
Number of subjects: 18621

Group type: EXPERIMENTAL
Intervention: Abnormal renal function (creatinine clearance <70 mL/min) in the NSE group
Number of subjects: 18621

Group type: COMPARATOR
Intervention: Creatinine clearance
Number of subjects: 18621
Study: 9721959

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 89

Group type: COMPARATOR
Intervention: Co-amoxiclav plus aminoglycoside
Number of subjects: 89
Study: 7992239

Group type: EXPERIMENTAL
Intervention: Diet rich in fish (250 g daily for six weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (bread enriched with selenium or normal diet)
Number of subjects: 32
Study: 2538300

Group type: EXPERIMENTAL
Intervention: Isocaloric diet rich in fibres (70 g/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isocaloric diet enriched by guar (9 g of guar added to 30 g of natural fibres/day)
Number of subjects: 12